Pfizer

Pharmaceuticals
PFE
$ 50 0.11
Share price
$ 283 bn
Market Cap
$ 296 bn
Enterprise Value

Carbon footprint

4 Ton
GHG emissions per $ 1 mln investment
0.14x the weighted average for S&P 500
FY2020
How is this calculated?
-5.7%
YOY change in GHG emissions
Weaker than the -8.7% weighted average for S&P 500
FY2020 vs. previous year

Primary Climate Goal

-4.3%
Proj. YOY change in GHG emissions (Scope 1 + 2)
Weaker than the -5.1% weighted average for S&P 500
FY2021
How is this calculated?

Pfizer aims to reduce Scope 1 + 2 by 46% by 2030 from a base year 2019


1.5°C
Pfizer's actual and proj. GHG emissions (Scope 1 + 2) (Kt of CO2e)

GHG emissions and Carbon intensity

Pfizer's GHG emissions (market-based) (Kt of CO2e)
Pfizer's Carbon intensity (Tons per 1 USDm)

Pfizer's carbon footprint

Pfizer reported Total CO2e Emissions - Market-Based Scope 1 + Scope 2 for the twelve months ending 31 December 2020 at 1,197 Kt (-72 /-5.7% y-o-y). Also positively, carbon intensity plunged to 29 t (-2.2 /-7.1% y-o-y).

Pfizer's Scope 3 emissions plunged to 3,818 Kt (-1,890 /-33.1% y-o-y). The parameter has been fairly volatile.

The company is committed to reducing Scope 1 + 2 by 46% by 2030 from a base year 2019, which translates into the estimated reduction of -51 Kt per annum over the period of FY2021 - FY2030. This science-based target is aligned with Paris Agreement to limit global warming to 1.5°C above pre-industrial levels.

Pfizer aims to achive carbon neutrality across its operations (Scope 1 + 2) in 2030. Companies normally become carbon neutral with the help of the acquisition of carbon offsets rather than absolute reductions in their own greenhouse emissions. Also, carbon neutrality does not include non-CO2 GHG emissions.

Company environmental metrics

Show more...